| Identification | Back Directory | [Name]
1H-Benzimidazole-2-propanoic acid, β-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (βS)- | [CAS]
480446-44-4 | [Synonyms]
UFP512
UFP-512
UFP 512
1H-Benzimidazole-2-propanoic acid, β-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (βS)- | [Molecular Formula]
C31H33N5O5 | [MOL File]
480446-44-4.mol | [Molecular Weight]
555.64 |
| Hazard Information | Back Directory | [Description]
UFP-512 is a novel selective delta-opioid (DOP) receptor agonist. UFP-512 is a promising drug prototype for exploring innovative treatments for mood disorders. | [Uses]
UFP-512 is a selective and potent σ-opioid receptor (DOP receptor) peptidic agonist with antidepressant- and anxiolytic-like effects. UFP-512 exhibits as a potent agonist on adenylyl cyclase inhibition and Erk1/2 activation. UFP-512 induces phosphorylation of DOP receptors on Ser363 with a low desensitization of the cAMP pathway. UFP-512 is promising for research of mood disorders[1]. | [References]
[1] Aguila B, et al. In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance. Br J Pharmacol. 2007 Dec;152(8):1312-24. DOI:10.1038/sj.bjp.0707497 |
|
|